Dan Leonard
Stock Analyst at UBS
(4.05)
# 568
Out of 5,111 analysts
308
Total ratings
57.47%
Success rate
9.77%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Buy | $170 → $180 | $139.19 | +29.32% | 23 | Nov 25, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $13 → $14 | $15.71 | -10.88% | 7 | Nov 7, 2025 | |
| TECH Bio-Techne | Maintains: Buy | $65 → $70 | $57.44 | +21.87% | 12 | Nov 6, 2025 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $44.96 | -4.36% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $100.00 | +10.00% | 11 | Oct 30, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $225 → $250 | $221.68 | +12.78% | 17 | Oct 29, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $570.16 | +3.48% | 18 | Oct 23, 2025 | |
| EXAS Exact Sciences | Maintains: Neutral | $61 → $53 | $101.76 | -47.92% | 10 | Aug 7, 2025 | |
| CERT Certara | Maintains: Buy | $18 → $15 | $8.66 | +73.21% | 10 | Aug 7, 2025 | |
| MEDP Medpace Holdings | Downgrades: Sell | $300 → $305 | $558.74 | -45.41% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $225 | $224.70 | +0.13% | 18 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,386.45 | -2.63% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $302.02 | +2.64% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $310.99 | -0.32% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $96.27 | +19.46% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $97.48 | +1.56% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $11.20 | +123.21% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $195.22 | -5.24% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $9.24 | -2.60% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $27.16 | +28.87% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $131.56 | +52.02% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $3.59 | +206.41% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $227.40 | -69.22% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $15.93 | -56.06% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $378.53 | -8.86% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $182.45 | +42.50% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $178.66 | -18.84% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $75.02 | +19.97% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $45.01 | +41.41% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $258.11 | +31.73% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $20.89 | +14.89% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $6.88 | +408.72% | 12 | Aug 14, 2019 |
Agilent Technologies
Nov 25, 2025
Maintains: Buy
Price Target: $170 → $180
Current: $139.19
Upside: +29.32%
10x Genomics
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $14
Current: $15.71
Upside: -10.88%
Bio-Techne
Nov 6, 2025
Maintains: Buy
Price Target: $65 → $70
Current: $57.44
Upside: +21.87%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $44.96
Upside: -4.36%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $100.00
Upside: +10.00%
IQVIA Holdings
Oct 29, 2025
Maintains: Buy
Price Target: $225 → $250
Current: $221.68
Upside: +12.78%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $570.16
Upside: +3.48%
Exact Sciences
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $101.76
Upside: -47.92%
Certara
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $8.66
Upside: +73.21%
Medpace Holdings
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $558.74
Upside: -45.41%
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $224.70
Upside: +0.13%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,386.45
Upside: -2.63%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $302.02
Upside: +2.64%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $310.99
Upside: -0.32%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $96.27
Upside: +19.46%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $97.48
Upside: +1.56%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $11.20
Upside: +123.21%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $195.22
Upside: -5.24%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $9.24
Upside: -2.60%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $27.16
Upside: +28.87%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $131.56
Upside: +52.02%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $3.59
Upside: +206.41%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $227.40
Upside: -69.22%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $15.93
Upside: -56.06%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $378.53
Upside: -8.86%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $182.45
Upside: +42.50%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $178.66
Upside: -18.84%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $75.02
Upside: +19.97%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $45.01
Upside: +41.41%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $258.11
Upside: +31.73%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $20.89
Upside: +14.89%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $6.88
Upside: +408.72%